Xenetic Biosciences (XBIO) Share-based Compensation (2014 - 2026)
Xenetic Biosciences' (XBIO) quarterly Share-based Compensation came in at $11312.0 in Q1 2026, down 41.24% YoY from $19251.0 in Q1 2025, and down 19.19% on a QoQ basis from $13998.0 in Q4 2025.
Xenetic Biosciences (XBIO) Share-based Compensation (2014 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of Share-based Compensation data on file, last reported at $11312.0 in Q1 2026.
- Quarterly Share-based Compensation fell 41.24% year-over-year to $11312.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56848.0 (down 50.13% YoY) and the FY2025 annual result came in at $64787.0, down 62.29% from the prior year.
- Share-based Compensation fell to $11312.0 in Q1 2026, from $13998.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $137364.0 in Q3 2022 to a low of $11312.0 in Q1 2026.
- A 5-year average of $61322.2 and a median of $68852.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation rose 23.61% — and 2025, when it plunged 75.02%.
- Tracing XBIO's Share-based Compensation over 5 years: stood at $118651.0 in 2022, then plunged by 37.15% to $74578.0 in 2023, then slumped by 66.33% to $25108.0 in 2024, then tumbled by 44.25% to $13998.0 in 2025, then dropped by 19.19% to $11312.0 in 2026.
- The last three Share-based Compensation figures came in at $11312.0 (Q1 2026), $13998.0 (Q4 2025), and $15855.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 51,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51,964.00 |
| Jun 30, 2026 | 51,964.00 |
| Mar 31, 2026 | 11,312.00 |
| Mar 31, 2026 | 11,312.00 |
| Dec 31, 2025 | 13,998.00 |
| Dec 31, 2025 | 13,998.00 |
| Sep 30, 2025 | 15,855.00 |
| Sep 30, 2025 | 15,855.00 |
| Jun 30, 2025 | 15,683.00 |
| Jun 30, 2025 | 15,683.00 |
| Mar 31, 2025 | 19,251.00 |
| Mar 31, 2025 | 19,251.00 |
| Dec 31, 2024 | 25,108.00 |
| Dec 31, 2024 | 25,108.00 |
| Sep 30, 2024 | 27,536.00 |
| Sep 30, 2024 | 27,536.00 |
| Jun 30, 2024 | 42,096.00 |
| Jun 30, 2024 | 42,096.00 |
| Mar 31, 2024 | 77,074.00 |
| Mar 31, 2024 | 77,074.00 |